Trelegy Ellipta vs Nucala
A side-by-side look at two respiratory medications advertised on TV. Informational only — not medical advice.
| US Trelegy Ellipta | US Nucala | |
|---|---|---|
| Generic name | fluticasone/umeclidinium/vilanterol | mepolizumab |
| Drug class | Inhaled Corticosteroid + LAMA + LABA | IL-5 Antagonist (Biologic) |
| Treats | COPD, asthma | Severe eosinophilic asthma, COPD, nasal polyps |
| Category | Respiratory | Respiratory |
| Manufacturer | GSK | GSK |
| Year approved | 2017 | 2015 |
| FDA warning | No boxed warning | No boxed warning |
| Est. TV ad spend | $200M | $75M |
| Common side effects | Thrush, Respiratory infections, Headache, Cough | Headache, Injection site reactions, Back pain, Fatigue |
Trelegy Ellipta
Frequently asked questions
Is Trelegy Ellipta or Nucala better?
Neither is universally "better." Trelegy Ellipta (fluticasone/umeclidinium/vilanterol) and Nucala (mepolizumab) are both used for respiratory, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Trelegy Ellipta and Nucala?
Trelegy Ellipta is a Inhaled Corticosteroid + LAMA + LABA made by GSK, while Nucala is a IL-5 Antagonist (Biologic) made by GSK. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Trelegy Ellipta has the larger estimated TV advertising budget of the two.